Skip to main content
. 2022 Nov 14;6(12):e801. doi: 10.1097/HS9.0000000000000801

Figure 5.

Figure 5.

Duration of response with acalabrutinib and IdR/BR. aBased on stratified Cox proportional hazards model, stratified by randomization stratification factors as recorded in interactive voice/web response system. bBased on stratified log-rank test, stratified by randomization stratification factors as recorded in interactive voice/web response system. BR = bendamustine plus rituximab; CI = confidence interval; DOR = duration of response; HR = hazard ratio; IdR = idelalisib plus rituximab; NR = not reached.